Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands

Molecular Pharmacology

Volumn 83, Issue 4, 2013, Pages 822-834

  Wootten, Denise ^a   Savage, Emilia E ^a   Willard, Francis S ^b   Bueno, Ana B ^c   Sloop, Kyle W ^b   Christopoulos, Arthur ^a   Sexton, Patrick M ^a  

^a MONASH UNIVERSITY   (Australia)

^b ELI LILLY AND COMPANY   (United States)

^c ELI LILLY AND COMPANY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIGAND;

ALLOSTERISM; ARTICLE; BINDING ASSAY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPETITIVE BEHAVIOR; CONTROLLED STUDY; HUMAN; HUMAN CELL; MODULATION; MOLECULAR WEIGHT; PARTIAL AGONISM; PHARMACOPHORE; PRIORITY JOURNAL;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; CYCLOBUTANES; HUMANS; LIGANDS; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION;

EID: 84875426039     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.084525     Document Type: Article

References (30)

1. Aurelio L, Valant C, Flynn BL, Sexton PM, Christopoulos A, and Scammells PJ (2009) Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. J Med Chem 52:4543-4547.
2. Avlani VA, McLoughlin DJ, Sexton PM, and Christopoulos A (2008) The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions. J Pharmacol Exp Ther 325:927-934.
3. Baggio LL and Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157.
4. Black JW and Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220:141-162.
5. Black J (1989) Drugs from emasculated hormones: the principle of syntopic antagonism. Science 245:486-493.
6. Buteau J, Foisy S, Joly E, and Prentki M (2003) Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52:124-132.
7. Chen D, Liao J, Li N, Zhou C, Liu Q, Wang G, Zhang R, Zhang S, Lin L, and Chen K et al. (2007) A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc Natl Acad Sci USA 104:943-948.
8. DeFronzo RA (1992) Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia 35:389-397.
9. Drucker DJ and Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705.
10. Drucker DJ, Philippe J, Mojsov S, Chick WL, and Habener JF (1987) Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 84:3434-3438.
11. Evans BA, Broxton N, Merlin J, Sato M, Hutchinson DS, Christopoulos A, and Summers RJ (2011) Quantification of functional selectivity at the human a(1A)-adrenoceptor. Mol Pharmacol 79:298-307.
12. Hoare SR (2005) Mechanisms of peptide and nonpeptide ligand binding to Class B Gprotein- coupled receptors. Drug Discov Today 10:417-427.
13. Holz GG, 4th, Kühtreiber WM, and Habener JF (1993) Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7-37). Nature 361:362-365.
14. Kenakin T (2011) Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336:296-302.
15. Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, and Novick S (2012) A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci 3:193-203.
16. Knudsen LB, Kiel D, Teng M, Behrens C, Bhumralkar D, Kodra JT, Holst JJ, Jeppesen CB, Johnson MD, and de Jong JC et al. (2007) Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci USA 104:937-942.
17. Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL, Miller LJ, Summers RJ, Christopoulos A, and Sexton PM (2010) Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol 78:456-465.
18. Koole C, Wootten D, Simms J, Valant C, Miller LJ, Christopoulos A, and Sexton PM (2011) Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allosteric rescue of loss of function mutation. Mol Pharmacol 80:486-497.
19. Leach K, Sexton PM, and Christopoulos A (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 28: 382-389.
20. Mapelli C, Natarajan SI, Meyer JP, Bastos MM, Bernatowicz MS, Lee VG, Pluscec J, Riexinger DJ, Sieber-McMaster ES, and Constantine KL et al. (2009) Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity. J Med Chem 52:7788-7799.
21. May LT, Avlani VA, Langmead CJ, Herdon HJ, Wood MD, Sexton PM, and Christopoulos A (2007) Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. Mol Pharmacol 72:463-476.
22. Montrose-Rafizadeh C, Avdonin P, Garant MJ, Rodgers BD, Kole S, Yang H, Levine MA, Schwindinger W, and Bernier M (1999) Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology 140: 1132-1140.
23. Park S, Dong X, Fisher TL, Dunn S, Omer AK, Weir G, and White MF (2006) Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J Biol Chem 281:1159-1168.
24. Quoyer J, Longuet C, Broca C, Linck N, Costes S, Varin E, Bockaert J, Bertrand G, and Dalle S (2010) GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells. J Biol Chem 285:1989-2002.
25. Rao M (2009) inventor, TransTech Pharma Inc., assignee. Ligands for the GLP-1 receptor and methods for discovery thereof. International patent application E, PCT/US2009/039905. 2009 Oct 15.
26. Sloop KW, Willard FS, Brenner MB, Ficorilli J, Valasek K, Showalter AD, Farb TB, Cao JX, Cox AL, and Michael MD et al. (2010) Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets. Diabetes 59:3099-3107.
27. Sonoda N, Imamura T, Yoshizaki T, Babendure JL, Lu JC, and Olefsky JM (2008) Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells. Proc Natl Acad Sci USA 105:6614-6619.
28. Werry TD, Gregory KJ, Sexton PM, and Christopoulos A (2005) Characterization of serotonin 5-HT2C receptor signaling to extracellular signal-regulated kinases 1 and 2. J Neurochem 93:1603-1615.
29. Willard FS, Bueno AB, and Sloop KW (2012a) Small molecule drug discovery at the glucagon-like peptide-1 receptor. Exp Diabetes Res 2012:709893.
30. Willard FS, Wootten D, Showalter AD, Savage EE, Ficorilli J, Farb TB, Bokvist K, Alsina-Fernandez J, Furness SGB, Christopoulos A, Sexton PM, and Sloop KW (2012b) Small molecule allosteric modulation of the glucagon-like peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin. Mol Pharmacol 82: 1066-1073.